Dr. McCullough Weighs In: The History & Future of GLP-1s

In a recent article by Dr. Peter McCullough, he explores the evolution of GLP-1 receptor agonists and their expanding role beyond diabetes treatment. The journey began in 2005 with the FDA approval of exenatide (Byetta), setting the stage for a new class of medications that regulate blood sugar and appetite. A Timeline of GLP-1 Advancements: 2005 – Exenatide (Byetta) approved for type 2 diabetes 2010 – Liraglutide (Victoza) enters the market 2017 – Semaglutide (Ozempic & oral Rybelsus) gains approval 2022 – Tirzepatide (Mounjaro) emerges as a dual-receptor agonist These drugs influence key metabolic pathways, offering benefits for both diabetes and weight loss. However, they come with limitations—most require injections, clinical oversight, and ongoing prescriptions. The Next Step: Retatrutide & The Power of Triple-Receptor Agonism

Continue reading